NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models.
- DOI
- 10.1186/s12935-026-04438-5
- Published
- 2026 Aug 7
- Container
- Cancer cell international
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12935-026-04438-5,
title = {NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models.},
author = {Lyndin M and Janicot M and Müller J and Schiemann P and Wennemuth G},
year = {2026},
journal = {Cancer cell international},
doi = {10.1186/s12935-026-04438-5},
url = {https://doi.org/10.1186/s12935-026-04438-5}
}RIS
TY - JOUR TI - NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models. AU - Lyndin M AU - Janicot M AU - Müller J AU - Schiemann P AU - Wennemuth G PY - 2026 JO - Cancer cell international DO - 10.1186/s12935-026-04438-5 UR - https://doi.org/10.1186/s12935-026-04438-5 ER -
APA
M, L., M, J., J, M., P, S., & G, W. (2026). NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models.. Cancer cell international. https://doi.org/10.1186/s12935-026-04438-5
Source records
- pubmed · retrieved 2026-09-26T08:35:19.256Z